COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
The cause of hypercoagulopathy with COVID-19 may be due to autoantibodies, new study shows, creating potential for increased demand for autoantibody testing.
The CDC’s Advisory Committee on Immunization Practices met Dec. 3, 2020, to determine COVID-19 vaccine allocation. Clinical laboratories may be among first to receive.
How at-home COVID-19 testing now authorized under FDA emergency use authorization and new tests coming to market may affect clinical laboratories.
New guidance positions FDA and now the NCI in process for those opting to use LDTs in their laboratories with or without FDA premarket review or authorization.
HHS Cue pilot program creates hybrid COVID-19 testing strategy, potentially fast tracks Cue into institutions and communities outside of five-state rollout.
Nov. 2, 2020, marks the third and final wave of rapid COVID-19 testing device distribution (to about 1,360 nursing homes), according to CMS. Chilly nursing home response may create opportunities for clinical labs.
The cause of hypercoagulopathy with COVID-19 may be due to autoantibodies, new study shows, creating potential for increased demand for autoantibody testing.
The CDC’s Advisory Committee on Immunization Practices met Dec. 3, 2020, to determine COVID-19 vaccine allocation. Clinical laboratories may be among first to receive.
How at-home COVID-19 testing now authorized under FDA emergency use authorization and new tests coming to market may affect clinical laboratories.
New guidance positions FDA and now the NCI in process for those opting to use LDTs in their laboratories with or without FDA premarket review or authorization.
HHS Cue pilot program creates hybrid COVID-19 testing strategy, potentially fast tracks Cue into institutions and communities outside of five-state rollout.
Nov. 2, 2020, marks the third and final wave of rapid COVID-19 testing device distribution (to about 1,360 nursing homes), according to CMS. Chilly nursing home response may create opportunities for clinical labs.
